Parallax Volatility Advisers, L.P. Sarepta Therapeutics, Inc. Call Options Transaction History

Parallax Volatility Advisers, L.P.

$53.5 Billion
Q3 2024

Call Options

28 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$124.33 - $156.75 $15.1 Million - $19 Million	-121,300 Reduced 69.35%	53,600 $6.69 Million
Q2 2024 Aug 14, 2024	BUY	$113.33 - $163.85 $11.9 Million - $17.1 Million	104,600 Added 148.79%	174,900 $27.6 Million
Q1 2024 May 15, 2024	BUY	$93.7 - $141.53 $3.91 Million - $5.9 Million	41,700 Added 145.8%	70,300 $9.1 Million
Q4 2023 Feb 14, 2024	BUY	$67.31 - $124.76 $1.78 Million - $3.31 Million	26,500 Added 1261.9%	28,600 $2.76 Million
Q3 2023 Nov 14, 2023	BUY	$102.5 - $123.59 $123,000 - $148,308	1,200 Added 133.33%	2,100 $254,000
Q2 2023 Aug 14, 2023	SELL	$106.4 - $157.19 $11 Million - $16.2 Million	-103,000 Reduced 99.13%	900 $103,000
Q1 2023 May 15, 2023	BUY	$117.53 - $155.99 $3.44 Million - $4.57 Million	29,300 Added 39.28%	103,900 $14.3 Million
Q4 2022 Feb 14, 2023	BUY	$100.86 - $132.13 $3.8 Million - $4.98 Million	37,700 Added 102.17%	74,600 $9.67 Million
Q3 2022 Nov 14, 2022	BUY	$75.71 - $119.24 $2.66 Million - $4.19 Million	35,100 Added 1950.0%	36,900 $4.08 Million
Q2 2022 Aug 15, 2022	SELL	$62.69 - $88.44 $6,269 - $8,844	-100 Reduced 5.26%	1,800 $135,000
Q1 2022 May 16, 2022	BUY	$63.15 - $90.42 $119,985 - $171,798	1,900 New	1,900 $148,000
Q4 2021 Feb 14, 2022	SELL	$77.28 - $99.42 $3.25 Million - $4.19 Million	-42,100 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$77.28 - $99.42 $1.75 Million - $2.25 Million	22,600 Added 115.9%	42,100 $3.79 Million
Q3 2021 Nov 15, 2021	SELL	$65.97 - $92.48 $3.3 Million - $4.62 Million	-50,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$65.97 - $92.48 $1.29 Million - $1.8 Million	19,500 New	19,500 $1.8 Million
Q2 2021 Aug 16, 2021	BUY	$69.38 - $86.75 $3.47 Million - $4.34 Million	50,000 New	50,000 $3.89 Million
Q1 2021 May 14, 2021	SELL	$72.25 - $168.95 $1.16 Million - $2.7 Million	-16,000 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$72.25 - $168.95 $809,200 - $1.89 Million	11,200 Added 233.33%	16,000 $1.19 Million
Q4 2020 Feb 16, 2021	BUY	$125.56 - $178.74 $602,688 - $857,952	4,800 New	4,800 $816,000
Q4 2020 Feb 16, 2021	SELL	$125.56 - $178.74 $13.1 Million - $18.6 Million	-104,100 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$127.12 - $172.34 $3.64 Million - $4.93 Million	28,600 Added 37.88%	104,100 $14.6 Million
Q2 2020 Aug 14, 2020	BUY	$93.0 - $171.7 $5.55 Million - $10.3 Million	59,700 Added 377.85%	75,500 $12.1 Million
Q1 2020 May 15, 2020	SELL	$82.38 - $131.64 $1.99 Million - $3.19 Million	-24,200 Reduced 60.5%	15,800 $1.55 Million
Q3 2019 Nov 14, 2019	BUY	$72.81 - $156.91 $1.46 Million - $3.14 Million	20,000 Added 100.0%	40,000 $3.01 Million
Q3 2018 Nov 14, 2018	SELL	$115.31 - $161.51 $3.29 Million - $4.6 Million	-28,500 Reduced 58.76%	20,000 $3.23 Million
Q2 2018 Aug 14, 2018	BUY	$71.74 - $153.69 $2.04 Million - $4.38 Million	28,500 Added 142.5%	48,500 $6.41 Million
Q4 2017 Feb 14, 2018	BUY	$47.64 - $56.75 $948,036 - $1.13 Million	19,900 Added 19900.0%	20,000 $1.11 Million
Q3 2017 Nov 14, 2017	BUY	$35.73 - $47.15 $3,572 - $4,715	100	100 $5,000

Others Institutions Holding SRPT

# of Institutions

529

Shares Held

84.2M

Call Options Held

2.06M

Put Options Held

1.52M

Black Rock Inc. New York, NY

10.3M
Shares

$1.23 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

8.97M
Shares

$1.07 Billion
0.02% of portfolio
Capital International Investors Los Angeles, CA

6.26M
Shares

$745 Million
0.16% of portfolio
Janus Henderson Group PLC London, X0

4.36M
Shares

$519 Million
0.29% of portfolio
State Street Corp Boston, MA

4.27M
Shares

$508 Million
0.02% of portfolio

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.4B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.

Account